Agoracom: Small Cap Investment - Zenith Epigenetics - Re: BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK

BearDownAZ

May 20, 2019 05:09PM

bfw

Rank: Vice President [?]

Points: 840 [?]

Votes: 19 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK

in response to

BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK

BearDownAZ

posted on May 21, 2019 05:37PM

Looks great for Zenith.

The buyout price here better start with a B.

bfw

5 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply